JPMorgan analyst Chris Schott views the post-earnings weakness in Eli Lilly (LLY) shares as a buying opportunity. While the results missed expectations, mostly on wholesaler destocking for Mounjaro and Zepbound, underlying volume trends for Eli Lilly’s business remain healthy, the analyst tells investors in a research note. The firm says that with capacity ramping and Lilly now increasing its demand generating activities as a result, it anticipates a “significant step up” in Q4 sales. JPMorgan keeps an Overweight rating on the shares with a $1,100 price target
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LLY:
- Eli Lilly price target lowered to $1,100 from $1,150 at BofA
- Eli Lilly price target lowered to $975 from $1,025 at Barclays
- Eli Lilly’s Robust Q3 2024 Revenue Growth Driven by New Products
- Alphabet, AMD report Q3 earnings beats: Morning Buzz
- H.C. Wainwright still ‘optimistic’ on Phase 2 data for AnaptysBio’s rosnilimab